# US 2013/0158040 A1 · Diazaindole inhibitors of crac

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158040 A1
- Document ID: US20130158040A1
- Status: Published application
- Kind: A1
- Application number: 13/716,548
- Filed: 2012-12-17
- Published: 2013-06-20
- Earliest claimed: 2011-12-20
- Assignees: Hoffmann-La Roche Inc.
- Inventors: Muzaffar Alam; Niala Bhagirath; Daisy Joe Du Bois; Ronald Charles Hawley; Ana Elena Minatti; Joshua Kennedy-Smith; Robert Stephen Wilhelm
- Web page: https://patentgrep.com/patent/US20130158040A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 11/00: Drugs for disorders of the respiratory system
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are compounds of Formula (I): useful for treatment of autoimmune and inflammatory diseases associated with IL-2 inhibition via modulation of calcium release-activated calcium (CRAC) channels. Also disclosed are methods of making and using the compounds for treatment of diseases associated with CRAC channels.

## Claims

### Claim 1

A compound of Formula (I):
wherein:
one of X or Y is C and the other is N;
Ar is unsubstituted cycloalkyl, unsubstituted phenyl or phenyl mono- or bi-substituted independently with halogen;
Ar′ is—phenyl, unsubstituted or mono- or bi-substituted independently with —SO2N(CH3)2, lower alkyl or —C(O)OCH3, or
heteroaryl, unsubstituted or mono- or bi-substituted independently with lower alkyl or haloalkyl;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein X is C and Y is N.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein X is N and Y is C.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein Ar is phenyl mono- or bi-substituted independently with halogen, and Ar′ is phenyl, unsubstituted or mono- or bi-substituted independently with —SO2N(CH3)2, lower alkyl or —C(O)OCH3.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein Ar is phenyl mono- or bi-substituted independently with halogen, and Ar′ is heteroaryl, unsubstituted or mono- or bi-substituted independently with lower alkyl or haloalkyl.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein is Ar cyclohexyl and Ar′ is phenyl, unsubstituted or mono- or bi-substituted independently with —SO2N(CH3)2, lower alkyl or —C(O)OCH3.

### Claim 7 (depends on 1)

The compound according to claim 1, wherein is Ar is cyclohexyl and Ar′ is heteroaryl, unsubstituted or mono- or bi-substituted independently with lower alkyl or haloalkyl.

### Claim 8 (depends on 1)

The compound according to claim 1, wherein Ar is phenyl bisubstitued independently with chlorine or fluorine.

### Claim 9 (depends on 1)

The compound according to claim 1, wherein Ar is cyclohexyl.

### Claim 10 (depends on 1)

The compound according to claim 1, wherein Ar′ is N,N-trimethyl-benzenesulfonamide or methyl-benzoic acid methyl ester.

### Claim 11 (depends on 1)

The compound according to claim 1, wherein Ar′ is pyrazolyl, unsubstituted or mono- or bi-substituted independently with methyl or —CF3.

### Claim 12 (depends on 1)

The compound according to claim 1, wherein said compound is:
4-[6-(2-chloro-6-fluoro-phenyl)-5H-pyrrolo[3,2-d]pyrimidin-2-yl]-3,N,N-trimethyl-benzenesulfonamide;
6-(2-Chloro-phenyl)-2-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine;
4-[6-(2-Chloro-phenyl)-5H-pyrrolo[2,3-b]pyrazin-2-yl]-3-methyl-benzoic acid methyl ester;
4-(6-(2-Chlorophenyl)-5H-pyrrolo[2,3-b]pyrazin-2-yl)-N,N,3-trimethylbenzenesulfonamide;
6-(2-chloro-6-fluorophenyl)-2-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)-5H-pyrrolo[2,3-b]pyrazine;
6-Cyclohexyl-2-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)-5H-pyrrolo[2,3-b]pyrazine; or
4-(6-cyclohexyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)-N,N,3-trimethylbenzenesulfonamide.

### Claim 13 (depends on 1)

A pharmaceutical composition, comprising a therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 14 (depends on 1)

A method for treating arthritis, comprising the step of administering a therapeutically effective amount of a compound according to claim 1 to a subject in need thereof.

### Claim 19 (depends on 1)

A method for treating a respiratory disorder selected from chronic obstructive pulmonary disorder (COPD), asthma, and bronchospasm, comprising the step of administering a therapeutically effective amount of a compound according to claim 1 to a subject in need thereof
